MoonLake Immunotherapeutics (MLTX) Operating Leases (2022 - 2026)
MoonLake Immunotherapeutics (MLTX) posted quarterly Operating Leases of $1.8 million for Q1 2026, up 56.3% year-over-year from $1.1 million in Q1 2025, and up 377.27% quarter-over-quarter from $374000.0 in Q4 2025.
MoonLake Immunotherapeutics (MLTX) Operating Leases (2022 - 2026) Analysis & Trends
MoonLake Immunotherapeutics' Operating Leases history runs 5 years deep, the most recent figure standing at $1.8 million for Q1 2026.
- In Q1 2026, Operating Leases rose 56.3% year-over-year to $1.8 million; the TTM figure through Mar 2026 stood at $1.8 million (up 56.3% YoY), while the FY2025 annual figure was $374000.0, down 74.35% from the prior year.
- Operating Leases for Q1 2026 stood at $1.8 million, up from $374000.0 in the prior quarter.
- The five-year high for Operating Leases was $3.7 million in Q1 2024, with the low at $13084.0 in Q3 2023.
- The 5-year median for Operating Leases is $1.3 million (2024), against an average of $1.4 million.
- The sharpest annual moves came in 2024 and 2025: Operating Leases jumped 14694.47% in 2024, then sank 74.89% in 2025.
- MoonLake Immunotherapeutics' Operating Leases stood at $128951.0 in 2022, then jumped by 1838.71% to $2.5 million in 2023, then slumped by 41.68% to $1.5 million in 2024, then sank by 74.35% to $374000.0 in 2025, then soared by 377.27% to $1.8 million in 2026.
- Business Quant data shows MLTX's Operating Leases at $1.8 million in Q1 2026, $374000.0 in Q4 2025, and $486000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | MoonLake Immunotherapeutics | 1.40 Bn | 864.68 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.02 Mn |
| Mar 31, 2026 | 1.79 Mn |
| Dec 31, 2025 | 374,000.00 |
| Sep 30, 2025 | 486,000.00 |
| Jun 30, 2025 | 2.39 Mn |
| Mar 31, 2025 | 1.14 Mn |
| Dec 31, 2024 | 1.46 Mn |
| Sep 30, 2024 | 1.94 Mn |
| Jun 30, 2024 | 3.34 Mn |
| Mar 31, 2024 | 3.66 Mn |
| Dec 31, 2023 | 2.50 Mn |
| Sep 30, 2023 | 13,084.00 |
| Jun 30, 2023 | 211,238.00 |
| Mar 31, 2023 | 91,081.00 |
| Dec 31, 2022 | 128,951.00 |